# Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial

> **NCT01908465** · PHASE4 · COMPLETED · sponsor: **KU Leuven** · enrollment: 200 (actual)

## Conditions studied

- Irritable Bowel Syndrome (IBS)

## Interventions

- **DRUG:** Ebastine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01908465
- **Lead sponsor:** KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2022-11-02
- **Final completion:** 2022-11-02
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01908465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01908465, "Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01908465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*